Transparency Document
NCCN Guidelines for Small Bowel Adenocarcinoma V.1.2025
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 4757 - Internal Request | SBA-D 1 of 9 | Comment to include checkpoint inhibitor immunotherapy/FDA-approved PD-1 inhibitors (cemiplimab-rwlc, retifanlimab-dlwr, tislelizumab-jsgr, toripalimab-tpzi) as treatment options for dMMR/MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype (eg, TMB>50 mut/Mb) | Change made |
Yes: 30 No: 0 Abstain:0 Absent:4 |
|
| 4758 - Internal Request | SBA-D 1 of 9 | Comment to include sotorasib and adagrasib as second-line/subsequent therapy options for KRAS G12C mutation positive metastatic SBA | Change made |
Yes: 30 No: 0 Abstain:0 Absent:4 |
|
| 4759 | SBA-D 1 of 9 |
Submission request from Bristol Myers Squibb (06/14/24): (request # 4203, 4204) Request to add repotrectinib as a preferred category 2A recommended first-line targeted treatment option for patients with NTRK-positive locally advanced or metastatic small bowel adenocarcinoma. |
Change not made |
Yes: 0 No: 30 Abstain:0 Absent:4 |
|
| 4768 - Internal Request | SBA-1, SBA-3 | Comment to include checkpoint inhibitor immunotherapy/FDA-approved agents (nivolumab ± ipilimumab, pembrolizumab, cemiplimab-rwlc, dostarlimab-gxly, retifanlimab-dlwr, toripalimab-tpzi, or tislelizumab-jsgr) as treatment options for locally unresectable or medically inoperable dMMR/MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype [eg, TMB>50 mut/Mb] disease | Change made |
Yes: 30 No: 0 Abstain:0 Absent:4 |